Vanda Pharmaceuticals Inc. (VNDA) stock forecast and price target
Price $3.99 · data as of November 13, 2026
12-month price target
Average target$11.50
Upside / downside+188.2%
Analysts5
ConsensusStrong buy
Low $4.50Average $11.50High $20.00
Gold marker: average target · white marker: today’s price ($3.99)
Analyst ratings
Strong buy 0Buy 4Hold 1Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-2.52 | — | $242M |
| Next fiscal year ends December 31, 2027 | $-0.74 | — | $316M |
| Next quarter ends December 31, 2026 | $-0.30 | — | $70M |
| Quarter after ends March 31, 2027 | $-0.25 | — | $72M |
Consensus of the analysts covering Vanda Pharmaceuticals, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Frequently asked questions
What is the Vanda Pharmaceuticals stock price target?
The average 12-month target from 5 analysts is $11.50, 188.2% above the current price of $3.99 Targets range from $4.50 to $20.00.
Is Vanda Pharmaceuticals a buy according to analysts?
The consensus rating is “Strong buy” (4 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Vanda Pharmaceuticals expected to earn?
Analysts expect EPS of $-2.52 for the fiscal year ending December 31, 2026 and $-0.74 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.